Vitekta and Tybost join singles club

Home»Health & treatment»HIV treatment»Vitekta and Tybost join singles club
02 Oct 2014

Two of Gilead Sciences HIV drugs — Vitekta (elvitegravir) and Tybost (cobicistat) — have been cleared by the US Food and Drug Administration (FDA).

Vitekta — an integrase inhibitor — has been approved for treatment-experienced HIV-positive adults and is indicated for use in combination with a treatment-boosting agent. Vitekta was well-tolerated in clinical studies.

Tybost, meanwhile, becomes the second treatment-boosting agent on the American market and as well being recommended to be used with Vitekta is also recommended to enhance two once-daily protease inhibitors, Reyataz (atazanavir) and Prezista (darunavir).

Both Vitekta and Tybost are available in Australia, but only as components of Stribild

For more details visit the FDA approval notices for Viteka and Tybost.